Nature Publication Supports Senolytic Approach for Cancer Treatment

A recent Nature Communications study strengthens the case for targeting senescent cells in cancer treatment — a core focus of Immorta Bio’s therapeutic strategy. The research, based on data from 120 prostate cancer patients, found that a population of immune-suppressive cells exhibited a senescent profile, suggesting they may play a role in cancer progression. This discovery underscores the potential of senolytic therapies, which work by selectively clearing these cells.

Immorta Bio is advancing this approach through SenoVax™, its proprietary senolytic immunotherapy. Preclinical studies have shown promising results across multiple cancer types — including lung, breast, skin, and glioma — with evidence of tumor reduction and regression in animal models.

With an Investigational New Drug (IND) application filed with the FDA, Immorta is preparing for clinical trials focused on advanced non-small cell lung cancer (NSCLC). According to Immorta’s scientific leadership, the Nature study validates their vision of restoring immune balance by eliminating senescent cells — not only to treat cancer, but to address the underlying biology of aging.